MovDisordV3, PubMed, Corpus, bibRecord, 003C53

Neuroleptic malignant syndrome in advanced Parkinson's disease.

Identifieur interne : 003C53 ( PubMed/Corpus ); précédent : 003C52; suivant : 003C54

Neuroleptic malignant syndrome in advanced Parkinson's disease.

Auteurs : P H Gordon ; S J Frucht

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2001.

RBID : pubmed:11746631

English descriptors

KwdEn :
- Adult, Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Humans, Levodopa (adverse effects), Levodopa (pharmacokinetics), Male, Neuroleptic Malignant Syndrome (etiology), Parkinson Disease (drug therapy), Secondary Prevention, Severity of Illness Index, Substance Withdrawal Syndrome.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , pharmacokinetics : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- etiology : Neuroleptic Malignant Syndrome.
- Adult, Humans, Male, Secondary Prevention, Severity of Illness Index, Substance Withdrawal Syndrome.

Abstract

Neuroleptic malignant syndrome is a serious complication of levodopa withdrawal in patients with Parkinson's disease. We report a patient with advanced parkinsonism who developed neuroleptic malignant syndrome in the setting of inadequate levodopa intake. His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa.

PubMed: 11746631

Links to Exploration step

pubmed:11746631

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroleptic malignant syndrome in advanced Parkinson's disease.</title>
<author><name sortKey="Gordon, P H" sort="Gordon, P H" uniqKey="Gordon P" first="P H" last="Gordon">P H Gordon</name>
<affiliation><nlm:affiliation>Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Frucht, S J" sort="Frucht, S J" uniqKey="Frucht S" first="S J" last="Frucht">S J Frucht</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2001">2001</date>
<idno type="RBID">pubmed:11746631</idno>
<idno type="pmid">11746631</idno>
<idno type="wicri:Area/PubMed/Corpus">003C53</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neuroleptic malignant syndrome in advanced Parkinson's disease.</title>
<author><name sortKey="Gordon, P H" sort="Gordon, P H" uniqKey="Gordon P" first="P H" last="Gordon">P H Gordon</name>
<affiliation><nlm:affiliation>Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Frucht, S J" sort="Frucht, S J" uniqKey="Frucht S" first="S J" last="Frucht">S J Frucht</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001" type="published">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (pharmacokinetics)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (pharmacokinetics)</term>
<term>Male</term>
<term>Neuroleptic Malignant Syndrome (etiology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Secondary Prevention</term>
<term>Severity of Illness Index</term>
<term>Substance Withdrawal Syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Neuroleptic Malignant Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Humans</term>
<term>Male</term>
<term>Secondary Prevention</term>
<term>Severity of Illness Index</term>
<term>Substance Withdrawal Syndrome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Neuroleptic malignant syndrome is a serious complication of levodopa withdrawal in patients with Parkinson's disease. We report a patient with advanced parkinsonism who developed neuroleptic malignant syndrome in the setting of inadequate levodopa intake. His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11746631</PMID>
<DateCreated><Year>2001</Year>
<Month>12</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted><Year>2002</Year>
<Month>02</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>16</Volume>
<Issue>5</Issue>
<PubDate><Year>2001</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Neuroleptic malignant syndrome in advanced Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>960-2</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Neuroleptic malignant syndrome is a serious complication of levodopa withdrawal in patients with Parkinson's disease. We report a patient with advanced parkinsonism who developed neuroleptic malignant syndrome in the setting of inadequate levodopa intake. His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa.</AbstractText>
<CopyrightInformation>Copyright 2001 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gordon</LastName>
<ForeName>P H</ForeName>
<Initials>PH</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Frucht</LastName>
<ForeName>S J</ForeName>
<Initials>SJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009459">Neuroleptic Malignant Syndrome</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D055502">Secondary Prevention</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D013375">Substance Withdrawal Syndrome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2002</Year>
<Month>2</Month>
<Day>14</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2001</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">11746631</ArticleId>
<ArticleId IdType="pii">10.1002/mds.1166</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C53 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003C53 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:11746631
   |texte=   Neuroleptic malignant syndrome in advanced Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:11746631" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Neuroleptic malignant syndrome in advanced Parkinson's disease.

Neuroleptic malignant syndrome in advanced Parkinson's disease.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki